



05-21-04

Docket No.: PF-0430-1 DIV

1642
Bw

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Hillman et al.

Title: NEW GLUTATHIONE S-TRANSFERASE

Serial No.: 09/441,723

Filing Date: November 16, 1999

Group Art Unit: 1642

Commissioner for Patents
USPTO
P.O. Box 1450
Alexandria, VA 22313-1450

CERTIFICATE UNDER 37 C.F.R. § 3.73(b),
REVOCATION OF POWER OF ATTORNEY AND
APPOINTMENT OF NEW ATTORNEYS

Sir:

The undersigned has reviewed all the documents in the chain of title of the above-identified patent application and, to the best of undersigned's knowledge and belief, title is in the assignee identified below.

Incyte Corporation, formerly known as Incyte Genomics, Inc., also formerly known as Incyte Pharmaceuticals, Inc., having a principal place of business located at 3160 Porter Drive, Palo Alto, California 94304, certifies that it is the assignee and owner of the entire right, title and interest in, to, and under the invention described and claimed in the above-identified application by virtue of an Assignment recorded at Reel 9094, Frame 0979, hereby revokes all previous powers of attorney and appoints those practitioners under Customer No. **22428** as attorneys/agents with full power of substitution to prosecute this application and to transact all business in the Patent and Trademark Office in connection therewith.

Please direct all correspondence to:

Michele M. Simkin, Esq.
Reg. No. 34,717
Customer No.: 22428
Foley & Lardner LLP
Washington Harbour
3000 K Street, N.W., Suite 500
Washington, D.C. 20007-5109

and direct all telephone calls and facsimile transmissions to: Foley & Lardner LLP; Phone: Tel: (202) 672-5300 Fax: (202) 672-5399 The undersigned (whose title is supplied below) is empowered to act on behalf of the assignee.


I hereby declare that all statements made herein are of my own knowledge are true and that all statements made on information and belief are believed to be true, and further that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine of imprisonment, or both, under Section 1001, Title 18, of the United States Code, and that such willful false statements may jeopardize the validity of the patent.

INCYTE CORPORATION

Date:

April 28 2004

By:



Patricia Anne Schreck
Executive VP, General Counsel